Dianthus Therapeutics Stock Forward View - Triple Exponential Smoothing
| DNTH Stock | 53.39 0.03 0.06% |
Dianthus Stock outlook is based on your current time horizon. We recommend always using this module together with an analysis of Dianthus Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
The RSI of Dianthus Therapeutics' stock price is under 68 suggesting that the stock is rather overbought by investors as of 1st of February 2026. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Dianthus, making its price go up or down. Momentum 68
Buy Stretched
Oversold | Overbought |
Using Dianthus Therapeutics hype-based prediction, you can estimate the value of Dianthus Therapeutics from the perspective of Dianthus Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Triple Exponential Smoothing forecasted value of Dianthus Therapeutics on the next trading day is expected to be 53.92 with a mean absolute deviation of 1.24 and the sum of the absolute errors of 73.45. Dianthus Therapeutics after-hype prediction price | USD 53.11 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Dianthus Therapeutics to cross-verify your projections. Dianthus Therapeutics Additional Predictive Modules
Most predictive techniques to examine Dianthus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Dianthus using various technical indicators. When you analyze Dianthus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Dianthus Therapeutics Triple Exponential Smoothing Price Forecast For the 2nd of February
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Dianthus Therapeutics on the next trading day is expected to be 53.92 with a mean absolute deviation of 1.24, mean absolute percentage error of 2.86, and the sum of the absolute errors of 73.45.Please note that although there have been many attempts to predict Dianthus Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Dianthus Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Dianthus Therapeutics Stock Forecast Pattern
| Backtest Dianthus Therapeutics | Dianthus Therapeutics Price Prediction | Buy or Sell Advice |
Dianthus Therapeutics Forecasted Value
In the context of forecasting Dianthus Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Dianthus Therapeutics' downside and upside margins for the forecasting period are 49.79 and 58.05, respectively. We have considered Dianthus Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Dianthus Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Dianthus Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 0.1968 |
| MAD | Mean absolute deviation | 1.2449 |
| MAPE | Mean absolute percentage error | 0.0293 |
| SAE | Sum of the absolute errors | 73.45 |
Predictive Modules for Dianthus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dianthus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dianthus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dianthus Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Dianthus Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Dianthus Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Dianthus Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Dianthus Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Dianthus Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Dianthus Therapeutics' historical news coverage. Dianthus Therapeutics' after-hype downside and upside margins for the prediction period are 48.98 and 57.24, respectively. We have considered Dianthus Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Dianthus Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Dianthus Therapeutics is based on 3 months time horizon.
Dianthus Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Dianthus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dianthus Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Dianthus Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.81 | 4.13 | 0.00 | 0.17 | 0 Events / Month | 4 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
53.39 | 53.11 | 0.47 |
|
Dianthus Therapeutics Hype Timeline
Dianthus Therapeutics is currently traded for 53.39. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.17. Dianthus is anticipated to decline in value after the next headline, with the price expected to drop to 53.11. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -0.47%, whereas the daily expected return is currently at 0.81%. The volatility of related hype on Dianthus Therapeutics is about 1976.08%, with the expected price after the next announcement by competition of 53.22. About 97.0% of the company shares are held by institutions such as insurance companies. The book value of Dianthus Therapeutics was currently reported as 12.75. The company recorded a loss per share of 3.5. Dianthus Therapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 12th of September 2023. Given the investment horizon of 90 days the next anticipated press release will be in a few days. Check out Historical Fundamental Analysis of Dianthus Therapeutics to cross-verify your projections.Dianthus Therapeutics Related Hype Analysis
Having access to credible news sources related to Dianthus Therapeutics' direct competition is more important than ever and may enhance your ability to predict Dianthus Therapeutics' future price movements. Getting to know how Dianthus Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Dianthus Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ELVN | Enliven Therapeutics | 0.04 | 10 per month | 4.58 | 0.07 | 6.28 | (7.81) | 54.92 | |
| TSHA | Taysha Gene Therapies | (0.16) | 10 per month | 0.00 | (0.01) | 7.92 | (8.03) | 21.14 | |
| SANA | Sana Biotechnology | 0.03 | 9 per month | 0.00 | (0.02) | 12.59 | (8.77) | 25.63 | |
| ATAI | ATAI Life Sciences | (0.08) | 9 per month | 0.00 | (0.20) | 4.91 | (5.54) | 16.19 | |
| NKTR | Nektar Therapeutics | (2.07) | 9 per month | 0.00 | (0.16) | 6.56 | (7.77) | 20.31 | |
| ANAB | AnaptysBio | 0.00 | 0 per month | 3.71 | 0.12 | 6.11 | (5.26) | 20.41 | |
| OCS | Oculis Holding AG | 0.00 | 0 per month | 1.29 | 0.23 | 5.79 | (2.58) | 15.08 | |
| BBOT | BridgeBio Oncology Therapeutics | 0.00 | 0 per month | 3.57 | (0) | 8.45 | (6.24) | 27.79 | |
| IMTX | Immatics NV | 0.15 | 9 per month | 0.00 | (0.02) | 7.31 | (6.47) | 30.34 | |
| TRML | Tourmaline Bio | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for Dianthus Therapeutics
For every potential investor in Dianthus, whether a beginner or expert, Dianthus Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Dianthus Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Dianthus. Basic forecasting techniques help filter out the noise by identifying Dianthus Therapeutics' price trends.Dianthus Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dianthus Therapeutics stock to make a market-neutral strategy. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Dianthus Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Dianthus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Dianthus Therapeutics shares will generate the highest return on investment. By undertsting and applying Dianthus Therapeutics stock market strength indicators, traders can identify Dianthus Therapeutics entry and exit signals to maximize returns.
Dianthus Therapeutics Risk Indicators
The analysis of Dianthus Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Dianthus Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting dianthus stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.81 | |||
| Semi Deviation | 2.3 | |||
| Standard Deviation | 4.13 | |||
| Variance | 17.07 | |||
| Downside Variance | 8.26 | |||
| Semi Variance | 5.29 | |||
| Expected Short fall | (3.49) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Dianthus Therapeutics
The number of cover stories for Dianthus Therapeutics depends on current market conditions and Dianthus Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Dianthus Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Dianthus Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Dianthus Therapeutics Short Properties
Dianthus Therapeutics' future price predictability will typically decrease when Dianthus Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Dianthus Therapeutics often depends not only on the future outlook of the potential Dianthus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dianthus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.3 M | |
| Cash And Short Term Investments | 275.2 M |
Check out Historical Fundamental Analysis of Dianthus Therapeutics to cross-verify your projections. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.